SAB Biotherapeutics Inc News - SABSW

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human...

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage...

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and...

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors...

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a...

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), today...

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1...

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage...

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by...

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a...

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd...

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

SIOUX FALLS, S.D., May 30, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a...

SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

SIOUX FALLS, S.D., May 19, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage...

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

SIOUX FALLS, S.D., May 16, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a...

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

SAB Biotherapeutics Inc (SABSW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

SABSW News

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

SABSW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

SAB Biotherapeutics Inc (SABSW) News

SAB Biotherapeutics Inc (SABSW)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

SABSW News

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

SABSW Discussion

Your Recent History